[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Beijing Municipal Administration of Hospitals\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":216},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,43,68,90,112,142,163,191],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100652606","targeting-ankrd11-reverses-hbv-specific-cd8-t-cell-dysfunction-and-tolerance-100652606",false,"NCT07777250","Targeting ANKRD11 Reverses HBV-Specific CD8+ T Cell Dysfunction and Tolerance","Inclusion Criteria:\n\n* HLA-A11+ healthy donors or patients with chronic HBV infection.\n\nExclusion Criteria:\n\n* Not HLA-A11 positive or not meeting the criteria for the designated study population；",true,"ALL","18 Years","65 Years",{"count":20,"type":21},3,"ESTIMATED","OBSERVATIONAL","Achieving a functional cure for chronic hepatitis B (CHB) is largely hindered by the irreversible functional exhaustion and immune tolerance of hepatitis B virus (HBV)-specific CD8+ T cells. In our previous studies, an in vivo CRISPR screen identified ANKRD11 for the first time as an \"epigenetic brake\" on CD8+ T-cell effector function. Loss of ANKRD11 markedly enhanced the expansion, effector function, and viral clearance capacity of HBV-specific T cells. Based on these findings, we hypothesize that ANKRD11 regulates the epigenetic program of T-cell exhaustion by restricting the activity of AP-1 family transcription factors, and that targeting ANKRD11 can reverse T-cell dysfunction and overcome immune tolerance.\n\nThis project will: (1) elucidate the epigenetic mechanisms by which ANKRD11 regulates T-cell exhaustion using conditional knockout mouse models and multi-omics approaches; (2) evaluate how ANKRD11 deficiency reshapes the differentiation trajectory and antiviral function of HBV-specific T cells in models of chronic HBV infection; and (3) develop a combinatorial gene-editing strategy integrating \"release of the brake\" with \"stepping on the accelerator\" to generate enhanced TCR-T cells and evaluate their efficacy and safety in humanized mouse models.The study is expected to define a novel mechanism by which ANKRD11 regulates T-cell exhaustion, establish an enhanced TCR-T therapeutic strategy, and provide a potential approach toward achieving a functional cure for chronic HBV infection.",[25],"Chronic Hepatitis B",[25,27,28,29,30],"CD8+ T Cell Exhaustion","ANKRD11","Epigenetic Regulation","TCR-T Cell Therapy","NOT_YET_RECRUITING","2026-08-17",{"date":34,"type":35},"2026-08-20","ACTUAL",{"date":37,"type":21},"2026-12",{"date":39,"type":21},"2028-08",{"name":41,"class":42},"Beijing Municipal Administration of Hospitals","OTHER_GOV",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100649266","study-on-clinical-and-pathological-features-of-primary-biliary-cholangitis-and-risk-factors-related-to-disease-progression-100649266","NCT07733882","Study on Clinical and Pathological Features of Primary Biliary Cholangitis and Risk Factors Related to Disease Progression","原发性胆汁性胆管炎临床、病理特征及病情进展相关危险因素研究","Inclusion Criteria:\n\n1. Met the diagnostic criteria for PBC according to the Guidelines for the Diagnosis and Treatment of Primary Biliary Cholangitis (2021) and the Guidelines for the Diagnosis and Treatment of Primary Biliary Cholangitis (2025 Edition), satisfying at least two of the following three criteria: ① biochemical evidence of cholestasis (elevated ALP and\u002For GGT) with imaging excluding extrahepatic or intrahepatic large bile duct obstruction; ② positive AMAs\u002FAMA-M2 or positivity for other PBC-specific autoantibodies (anti-gp210 or anti-sp100); ③ histologic evidence of non-suppurative destructive cholangitis and small bile duct destruction. (2) Underwent liver biopsy with a complete pathological report. (3) Had complete clinical data with missing values for key variables not exceeding 20%.\n\nExclusion Criteria:\n\n1. Concomitant other liver diseases, such as chronic hepatitis B, hepatitis C, hepatitis D, hepatitis E, alcoholic liver disease, non-alcoholic fatty liver disease, drug-induced liver injury, autoimmune hepatitis, primary hemochromatosis, or Wilson's disease. (2) Concurrent non-hepatotropic viral infections causing liver injury, including Epstein-Barr virus, cytomegalovirus, and human immunodeficiency virus. (3) Concurrent liver malignancy. (4) Age \\\u003C 18 years. (5) Severely incomplete clinical data with missing values for key variables exceeding 20%.",{"count":51,"type":21},300,"Primary biliary cholangitis (PBC) is a chronic autoimmune intrahepatic cholestatic liver disease characterized by progressive, non-suppurative, destructive cholangitis, potentially leading to fibrosis, cirrhosis, and liver failure. It predominantly affects middle-aged and elderly women, with highly variable progression rates: some patients remain stable long-term, while others rapidly develop portal hypertension and decompensation. Early risk factor identification and accurate risk stratification are essential for improving prognosis.\n\nLarge-scale, multi-dimensional (clinical-pathological-laboratory) studies on PBC progression risk factors in the Chinese population remain scarce. The associations of histological stage, autoantibody profiles, and biochemical response with prognosis require further clarification.\n\nThis retrospective observational study will enroll PBC patients with histologically confirmed diagnosis via liver biopsy at Beijing Ditan Hospital, Capital Medical University, from January 2015 to June 2026. We will systematically analyze clinical, laboratory, autoantibody, and pathological features. Univariate and multivariate logistic\u002FCox regression will be used to identify independent risk factors, aiming to establish a progression risk prediction model tailored to Chinese PBC patients. This model will support early identification of high-risk individuals and guide personalized treatment and follow-up strategies in clinical practice.",[54],"PBC",[56,57,58],"Primary Biliary Cholangitis (PBC)","Disease progression","Risk factors","2026-08-03",{"date":61,"type":35},"2026-08-04",{"date":63,"type":21},"2026-08",{"date":65,"type":21},"2027-07-01",{"name":41,"class":42},1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":86,"completionDateStruct":87,"leadSponsor":89,"locationsCount":67},"100650278","study-on-clinicopathological-features-influencing-factors-and-clinical-outcomes-in-patients-with-psvd-100650278","NCT07744048","Study on Clinicopathological Features, Influencing Factors and Clinical Outcomes in Patients With PSVD","Study on Clinicopathological Features, Influencing Factors and Clinical Outcomes in Patients With Porto-sinusoidal Vascular Disease (PSVD)","Inclusion Criteria:\n\n1. Patients histopathologically diagnosed with porto-sinusoidal vascular disorder (PSVD) via liver needle biopsy;\n2. Liver biopsy specimen length ≥ 10 mm (or assessed as diagnostically adequate by a pathologist), with no histological evidence of cirrhosis;\n3. Meeting the established diagnostic criteria for PSVD.\n\nExclusion Criteria:\n\n1. Concomitant Budd-Chiari syndrome or other hepatic venous outflow obstruction diseases;\n2. Concomitant congenital hepatic fibrosis, hepatic sarcoidosis, or sinusoidal obstruction syndrome;\n3. Concomitant hepatocellular carcinoma or other hepatic malignancies;\n4. Age \\\u003C 18 years;\n5. Severe deficiency of clinical data that precludes valid analysis.",{"count":76,"type":21},150,"This retrospective-prospective cohort study investigates portal sinusoidal vascular disorder (PSVD), a liver vascular disease definitively diagnosed via liver biopsy. Addressing PSVD's poorly defined natural history, unclear prognostic determinants and the scarcity of large-scale systematic research in China, the study enrolls histopathologically confirmed patients, collects baseline clinicopathological, laboratory and imaging data, tracks endpoints including transplant-free survival, liver-related events and portal vein thrombosis changes, and conducts prognostic analyses using Cox regression, Kaplan-Meier method and Fine-Gray model, aiming to characterize disease features, identify key prognostic factors, verify high-risk subgroups with inferior outcomes, and support precise clinical management while filling relevant domestic research gaps.",[79],"Porto-Sinusoidal Vascular Diseases",[81,82,83],"Porto-sinusoidal vascular disorder","PSVD","INCPH","2026-08-01",{"date":61,"type":35},{"date":84,"type":21},{"date":88,"type":21},"2028-07-30",{"name":41,"class":42},{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":109,"leadSponsor":111,"locationsCount":67},"100646774","a-study-on-the-consistency-evaluation-of-digital-pcr-technology-for-quantitative-detection-of-hbv-nucleic-acid-100646774","NCT07684209","A Study on the Consistency Evaluation of Digital PCR Technology for Quantitative Detection of HBV Nucleic Acid","A Study on the Consistency Evaluation of Digital PCR Technology for Quantitative Detection of Hepatitis B Virus Nucleic Acid","Inclusion Criteria:\n\n1. Patients who have been diagnosed with chronic hepatitis B (in accordance with the diagnostic criteria of the \"Chronic Hepatitis B Prevention and Treatment Guidelines (2022 Edition)\") and are currently receiving NAs antiviral treatment for ≥ 6 months or have not received treatment and are ≥ 18 years old;\n2. Remaining samples (serum) that have undergone combas HBV DNA testing and have clear test results, with the sample collection time frozen for ≤ 6 months;\n3. The remaining sample volume is sufficient (≥ 1.0 mL), sufficient for digital PCR testing and necessary duplicate testing;\n4. Samples from the same patient at different time points can be included as independent samples, but the sampling interval time needs to be recorded.\n\nExclusion Criteria:\n\n1. Combine other liver virus infections such as HCV, HDV or HIV;\n2. Poor sample quality, such as severe hemolysis, lipemia or repeated freezing and thawing ≥ 3 times;\n3. The samples were not properly frozen and stored (-80℃) after collection or the temperature records were missing;\n4. The clinical information is severely lacking, making it impossible to confirm the diagnosis and treatment status;\n5. The duplicate samples already included at the same time point (only the first included sample is retained).",{"count":98,"type":21},200,"The research plan aims to evaluate the consistency of the digital PCR-based hepatitis B virus nucleic acid quantification technique with the existing Roche qPCR-based detection method. Approximately 200 samples of residual serum from patients with chronic hepatitis B, covering high, medium, low, and those below the Roche lower limit concentration or undetectable, will be collected. The two methods will be used for parallel testing. The main objective is to evaluate the quantitative consistency of the two methods within the quantifiable range of Roche (≥ 20 IU\u002FmL); the secondary objectives include evaluating the qualitative detection rate of samples with concentrations below 20 IU\u002FmL or undetectable nucleic acid.",[101],"Chronic Hepatitis b",[103,101,104],"Digital PCR","Combas TaqMan HBV DNA Test","2026-07-03",{"date":107,"type":35},"2026-07-07",{"date":84,"type":21},{"date":110,"type":21},"2028-08-01",{"name":41,"class":42},{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":16,"minAge":120,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":124,"phases":125,"briefSummary":127,"conditions":128,"keywords":130,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":67},"100587024","alzheimers-disease-treated-with-vagus-nerve-stimulation-100587024","NCT06923007","Alzheimer's Disease Treated With Vagus Nerve Stimulation","Study on the Safety and Efficacy of VNS in the Treatment of Mild and Moderate AD Patients; a Multi-center, Randomized, Double-blind, Placebo Parallel Control Trial","Advant","Inclusion Criteria:\n\n1. Age: 50-80 years\n2. Subjects conform to the diagnostic criteria for AD established by the National Institute on Aging and the Alzheimer's Association \\[National Institution Aging and Alzheimer's Association (NIA-AA)\\]\n3. There is mild to moderate cognitive impairment, and the clinical cognitive rating scale \\[Clinical Dementia Rating (CDR)\\] score is 0.5-2.\n4. Stable use of the drug for more than 1 month, and no plan to change the medication within 6 months after randomization\n5. The informed consent form is signed, and the patient complies with the requirements.\n\nExclusion Criteria:\n\n1. Dementia caused by other reasons, including vascular dementia, central nervous system infections (such as AIDS, syphilis, etc.), Creutzfeldt-Jakob disease, Huntington's disease and Parkinson's disease, dementia with Lewy bodies, traumatic brain injury dementia, other physical and chemical factors (such as drug poisoning, alcohol poisoning, carbon monoxide poisoning, etc.), significant physical illnesses (such as hepatic encephalopathy, pulmonary encephalopathy, etc.), intracranial space-occupying lesions (such as subdural hematoma, brain tumor), endocrine system disorders (such as thyroid disease, parathyroid disease), and dementia due to vitamin deficiency or any other cause.\n2. The presence of a serious or unstable disease, including cardiovascular, liver, kidney, gastrointestinal, respiratory, endocrine, neurological (AD-derived cognitive impairment excluded), psychiatric, immune or blood disorders, and other diseases that the investigator considers may affect the analysis results of this study, or life expectancy \\\u003C 24 months.\n3. A history of cancer within 5 years, except for non-metastatic basal cell carcinoma and\u002For squamous cell carcinoma, cervical carcinoma in situ, non-progressive prostate cancer, or other cancers with low risk of recurrence or spread.\n4. The subject has been diagnosed with any primary mental disorder other than AD-related cognitive impairment. If the investigator deems that the presence of this mental disorder or symptom may affect the interpretation of VNS efficacy, cognitive assessment, or the subject's ability to complete the study, then the subject imust be excluded. Subjects with a history of schizophrenia or other chronic psychiatric conditions are also excluded.\n5. Subjects who are judged by the investigator to have suicidal tendencies\n6. Illiteracy or insufficient education to complete the scale assessment\n7. Having a history of alcohol or drug abuse (excluding smoking history) within 2 years prior to the screening visit\n8. A history of multiple or severe drug allergy, obvious atopic allergic constitution or severe hypersensitivity after treatment (including but not limited to severe polymorphic erythema, linear IgA dermatosis, toxic epidermal necrolysis and\u002For exfoliative dermatitis) with clinical significance\n9. Important abnormalities that may be clinically significant and harmful to the subject, affect the study, or suggest other evidence of etiology of dementia during screening, such as physical examination or neurological examination, vital signs, ECG or clinical laboratory test results (determined by the investigator)\n10. Screening MRI results showing significant abnormalities suggest another potential cause of progressive cognitive impairment, or findings with clinical significance that may affect the participants ability to safely participate in the study. For example, more than two infarcts larger than 2 cm in diameter, infarcts in critical areas such as the thalamus, hippocampus, internal olfactory cortex, parahippocampal cortex, angular gyrus, or other gray matter nuclei in the subcortical regions, as well as a score of \\> 2 on the Fazekas Scale\n11. Any MRI contraindications, including claustrophobia, or the presence of prohibited metal (ferromagnetic) implant\u002Fcardiac pacemakers\n12. There are contraindications for VNS surgery, such as left vagus nerve injury, severe infection at the surgical site, and severe heart, lung, liver, kidney or other system dysfunction that cannot tolerate general anesthesia surgery.\n13. Currently participating in other interventional clinical trials, or any other type of medical research that is considered scientifically or medically incompatible with this study\n14. Other reasons that hinder the completion of this study, such as lack of stable caregivers\n15. Female subjects who are pregnant or planning to become pregnant\n16. Research center staff members and\u002For their immediate family members directly related to this study. Immediate family members are spouses, parents, children, or siblings, whether biological or legally adopted relatives.","50 Years","80 Years",{"count":123,"type":21},74,"INTERVENTIONAL",[126],"NA","The goal of this clinical trial is to evaluate the safety and efficacy of vagus nerve stimulation (VNS) for treating Alzheimer's disease (AD) in patients aged 50-80 years with mild cognitive impairment to moderate Alzheimer's disease. The main questions it aims to answer are:\n\nIs the change from baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog14) score at 6 months post-randomization better in the VNS group compared to the sham stimulation group? Is the change from baseline in scores of other cognitive function, neuropsychiatric symptom, or activities of daily living scales at 6 months post-randomization better in the VNS group compared to the sham stimulation group? Researchers will compare the group receiving vagus nerve stimulation (active VNS group) and the group receiving sham vagus nerve stimulation (sham VNS group) to see if VNS is more effective in improving cognitive function, neuropsychiatric symptoms, or activities of daily living.\n\nParticipants will:\n\nUndergo screening assessments (including medical history, physical exams, cognitive and behavioral scale assessments, imaging, etc.).\n\nUndergo surgery for VNS device implantation. Be randomized to either the active VNS or sham VNS group and receive the corresponding stimulation treatment for 6 months (while continuing standard AD medication).\n\nAttend multiple follow-up visits during the study (baseline, randomization day, 3 months, and 6 months post-randomization) for clinical scale assessments.\n\nPotentially provide biological samples (blood, CSF) and undergo additional auxiliary examinations (e.g., MRI, EEG, PET) at specific time points.",[129],"Alzheimer Disease (AD)",[131,132],"VNS","vagus nerve stimulation","RECRUITING","2025-06-03",{"date":136,"type":35},"2025-06-06",{"date":138,"type":35},"2025-05-07",{"date":140,"type":21},"2027-12",{"name":41,"class":42},{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":149,"targetDuration":4,"studyType":124,"phases":151,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":67},"100577828","research-on-clinical-recovery-and-maintenance-strategies-for-chb-100577828","NCT06803368","Research on Clinical Recovery and Maintenance Strategies for CHB","Research on Clinical Recovery and Maintenance Strategies for Chronic Hepatitis B","Inclusion Criteria:\n\n* Age between 18 and 65 years old;\n* Gender is not limited;\n* CHB patients who meet the diagnostic criteria of the 2019 edition of the Guidelines for the Prevention and Treatment of Chronic Hepatitis B \\[5\\];\n* Confirmed interferon treatment resulted in HBsAg disappearance, HBeAg negativity, and HBV DNA below the lower detection limit and cessation Patients treated with interferon;\n* Sign a written informed consent form.\n\nExclusion Criteria:\n\n* Merge with other hepatitis virus (HCV, HDV) infections;\n* Autoimmune liver disease;\n* HIV infection;\n* Long term alcohol abuse and\u002For other liver damaging drugs;\n* Mental illness;\n* Evidence of liver tumors (liver cancer or AFP\\>100ng\u002Fml);\n* Decompensated cirrhosis;\n* Individuals with serious diseases of the heart, brain, lungs, kidneys, and other systems who cannot participate in long-term follow-up.",{"count":150,"type":21},285,[126],"Collect basic information of patients before antiviral treatment and when HBsAg disappears, and divide them into three groups A, B, and C based on baseline anti HBs titers after informed consent. During the follow-up period of all patients, clinical biochemistry, virology (HBVDNA, HBVRNA), serological indicators (HBsAg, anti HBs, HBeAg, anti HBe, HBcrAg, anti HBc), AFP, Fibroscan, liver imaging examinations will be conducted every 3-6 months, and blood samples will be retained for monitoring the frequency of immune cells (pDC, Treg) and the expression of functional molecules, as well as cytokines (IFN - γ, IP-10, IL-10, and TGF - β). Observe the sustained response rate and recurrence rate of virological and serological indicators, as well as the incidence of hepatitis and liver cancer during the follow-up period.",[101,154],"Hepatitis B Vaccine","2025-01-26",{"date":157,"type":35},"2025-01-31",{"date":159,"type":35},"2024-11-01",{"date":161,"type":21},"2027-10-30",{"name":41,"class":42},{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":170,"enrollmentInfo":171,"targetDuration":173,"studyType":22,"phases":4,"briefSummary":174,"conditions":175,"keywords":177,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":67},"100570429","establishment-of-precise-histological-evaluation-criteria-for-nash-fibrosis-reversal-100570429","NCT06707129","Establishment of Precise Histological Evaluation Criteria for NASH Fibrosis Reversal","Establishment of Precise Histological Evaluation Criteria for Reversal of NASH Fibrosis","Inclusion Criteria:\n\n* Aged between 18 and 70 years at the time of liver biopsy;\n* Gender is not limited;\n* Hepatic perforation suggested that NASH complicated with fibrosis stage F2-4;\n* Signed written informed consent.\n\nExclusion Criteria:\n\n* Combined HCV infection, HIV infection, alcoholic liver disease, autoimmune liver disease, genetic metabolic liver disease Disease, drug-induced liver injury and other chronic liver diseases;\n* Women during pregnancy;\n* There are the following conditions before liver perforation: HCC or possible HCC (imaging suggests malignant liver occupation); decompensation of cirrhosis (ascites, hepatic encephalopathy, gastrointestinal bleeding, hepatorenal syndrome, etc.); Patients with other malignant tumors; Recipients of liver transplantation;\n* Patients considered by the investigator to be unsuitable for this study.","70 Years",{"count":172,"type":21},50,"12 Months","Collect confirmed cases of NAFLD patients and enroll them in the study. Select patients with NASH and fibrosis stage F2-4 confirmed by liver biopsy, and collect clinical and pathological data for relevant evaluation and definition. Establish a NASH \"fibrosis reversal\" pathological evaluation system, based on a new reversal standard, establish non-invasive alternative indicators, and observe indicators.",[176],"Non-alcoholic Fatty Liver Disease",[178,179,180,181,182],"non-alcoholic fatty liver disease","nonalcoholic steatohepatitis","liver biopsy","Fibrosis reversal","histopathology","2024-11-23",{"date":185,"type":35},"2024-11-27",{"date":187,"type":35},"2024-08-01",{"date":189,"type":21},"2027-08-31",{"name":41,"class":42},{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":121,"enrollmentInfo":198,"targetDuration":4,"studyType":124,"phases":200,"briefSummary":201,"conditions":202,"keywords":205,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":67},"100554426","deep-brain-stimulation-of-the-dentate-nucleus-for-motor-rehabilitation-after-stroke-100554426","NCT06498934","Deep Brain Stimulation of the Dentate Nucleus for Motor Rehabilitation After Stroke","Deep Brain Stimulation of Cerebellar Dentate Nucleus Promotes Upper Limb Motor Function Recovery After Ischemic Stroke: a Randomized, Double-blind, Sham-controlled Trial","Inclusion Criteria:\n\n1. Within the first year to 3 years after the first stroke;\n2. Unilateral infarction located in the territory of the middle cerebral artery, but not involving the cerebellum, thalamus, and brainstem;\n3. Aged 18-80 years;\n4. TMS standard: TMS induces muscle evoked potential (MEP). In the contracted state of the paralyzed muscle (maximum voluntary contraction of 20-50%), a reliable standard MEP (in 5\u002F10 trials with 50-100uv) can be induced;\n5. Researchers determine the medical and neurological condition of the participant to be stable based on the participant's medical history, physical examination, and neurological examination;\n6. Moderate-severe unilateral upper limb paralysis, i.e., the Fugl-Meyer Assessment (FMA-UE) scale score is ≤47;\n7. The distal extremity of the limb has some degree of motor function (flexion of the elbow joint or extension of the elbow joint or partial finger flexion with FMA-UE ≥1);\n8. mRS\\\u003C4 points, able to cooperate with assessment and rehabilitation;\n9. No spasticity or mild spasticity in any part of the affected limb (intramuscular rotator muscle and adductor muscle of the shoulder joint, flexor muscle of the elbow joint, flexor muscle of the wrist joint or finger flexor muscle), modified Ashworth scale (MAS) \\\u003C4 points;\n10. MMSE\\>24 points.\n\nExclusion Criteria:\n\n1. Primary hemorrhagic stroke or severe hemorrhagic conversion;\n2. Any progressive neurological or somatic disease that impairs the function of the affected limb other than stroke;\n3. Moderate to severe neglect or disinhibition of the affected limb;\n4. Any other neurological disorder that may compromise study safety, including central nervous system vasculitis, intracranial tumors, intracranial aneurysms, multiple sclerosis, or arteriovenous malformations;\n5. Pain intensity on the affected limb NRS ≥5 or severe sensory disturbance, NIHSS (item 8) = 2;\n6. Exclusion of cardioembolic stroke, patients requiring long-term anticoagulation;\n7. Unable to stop anticoagulation treatment at least 10 days prior to surgery (i.e., antiplatelet and\u002For anticoagulant therapy);\n8. Seizure(s) after stroke or potential risk of seizure(s);\n9. Switching to oral spasticity medication within 2 weeks of enrollment, or injection of botulinum toxin in the affected arm within 4 months, and\u002For intention to start taking spasticity medication or inject botulinum toxin during the study follow-up period or within 12 months after implantation;\n10. The presence of active psychosis that may affect treatment effect, such as psychosis or severe personality disorder;\n11. Untreated or inadequately treated depression, i.e., Beck Depression Inventory score of 20 or more at admission;\n12. Diagnosis of dementia;\n13. Uncontrolled hypertension or history of cardiovascular disease for a long time;\n14. MRI contraindications, such as implanted metal devices or electronic devices (pacemakers, defibrillators, spinal cord stimulators);\n15. Participated in another device, biological, or drug study within 30 days of consenting to participate in the current study;\n16. Non-pregnant or fertile women must use acceptable contraception, and pregnant women are excluded or terminated from the study;\n17. Received decompressive craniectomy;\n18. The patient has severe cerebral small vessel disease, basilar artery vascular disease, and\u002For any other structural abnormalities of the cerebellum, cerebellar peduncles, and brainstem that prevent safe placement of DBS;\n19. The investigator determines that the patient has a condition that would significantly increase the risk of study non-compliance, study safety, and\u002For study integrity. For the safety of the subject, for example, if the subject experiences an exacerbation of their condition, a serious adverse event, or poor compliance.",{"count":199,"type":21},52,[126],"The goal of this clinical trial is to learn if deep brain stimulation of the dentate nucleus (DN-DBS) works to promote chronic post-stroke upper limb motor function in adults. It will also learn about the safety of DN-DBS. The main questions it aims to answer are:\n\nDoes DN-DBS paired with rehabilitation improve the upper limb motor function of participants more than rehabilitation only? What medical problems do participants have when using DN-DBS for post-stroke rehabilitation?\n\nResearchers will compare real DN-DBS+rehabilitation to sham DN-DBS+rehabilitation (electrodes will be implanted, but no electrical current is given) to see if DN-DBS works to promote chronic post-stroke upper limb motor function.\n\nParticipants will:\n\nUndergo unilateral DN-DBS surgery Take real DN-DBS+rehabilitation or sham DN-DBS+rehabilitation as treatment for 6 months Visit the clinic every month during the DN-DBS+rehabilitation (treatment) period for programing, checkups and tests Visit the clinic at Day 1, 30, 90 and 365 after treatment period for checkups and tests",[203,204],"Stroke","Upper Extremity Paresis",[206,207],"deep brain stimulation","the dentate nucleus","2024-07-17",{"date":210,"type":35},"2024-07-18",{"date":212,"type":21},"2024-09-01",{"date":214,"type":21},"2027-12-31",{"name":41,"class":42},""]